Novel Device Pathways
The De Novo pathway is designed for novel, low-to-moderate risk devices that lack a valid predicate for 510(k) clearance but don't require the full PMA burden. Used strategically, it doesn't just get you to market — it creates a competitive moat by establishing your device as the predicate for every future competitor.
Assess Your De Novo EligibilityPathway Analysis
The De Novo pathway, established under Section 513(f)(2) of the FD&C Act and 21 CFR Part 860, Subpart D, serves a specific and often underutilized function in the regulatory landscape. It is the appropriate pathway for devices that cannot demonstrate substantial equivalence to an existing predicate (disqualifying 510(k)) but whose risk profile can be adequately mitigated by general controls plus device-specific special controls — making full PMA unnecessary.
Two routes lead to De Novo: the direct pathway, where a sponsor submits a De Novo request directly based on device risk analysis, and the NSE pathway, where a 510(k) was filed, received a Not Substantially Equivalent (NSE) determination, and the sponsor then pursues De Novo. In most cases, the direct pathway is preferable — the NSE route wastes 510(k) review time and resources on a submission FDA will ultimately decline.
The eligibility analysis requires answering two questions: Is there a valid predicate with matching intended use and similar technological characteristics? If not, can special controls be developed that, in combination with general controls, provide reasonable assurance of safety and effectiveness? The second question is where most De Novo strategy work is done.
A De Novo grant has a consequence that many sponsors underestimate: FDA simultaneously creates a new device classification and publishes it in the Code of Federal Regulations. The De Novo applicant's device becomes the first classified device in that product code — and by extension, it becomes the predicate device against which every future competitor must demonstrate substantial equivalence in their 510(k) submissions.
This means the first company through De Novo for a novel device type effectively sets the regulatory standard for the category. Competitors must compare their devices to yours, reference your special controls, and demonstrate they meet or exceed the performance criteria your application established. This is a meaningful first-mover advantage that extends well beyond the time to market itself — it shapes competitive positioning for years.
Special controls are the regulatory heart of a De Novo application. They are the device-specific requirements — performance standards, design characteristics, testing requirements, labeling specifications — that FDA determines are necessary to provide reasonable assurance of safety and effectiveness for the device type. Writing effective special controls requires understanding both what FDA will accept and what provides genuine risk mitigation.
Special controls must be testable and verifiable — vague controls like "the device shall be biocompatible" are insufficient. They need to specify the standard (ISO 10993 series), the test methods, the acceptance criteria, and who is responsible for conducting and documenting the testing. We develop special controls frameworks that are defensible to FDA reviewers and operationally achievable for your engineering team.
FDA's acceptance review for De Novo requests assesses whether the submission is administratively complete and appropriate for substantive review. A Refuse to Accept (RTA) decision restarts the clock and signals that the submission lacks critical elements. We conduct Pre-De Novo meetings through the Q-Submission program to align with FDA on pathway appropriateness, evidence requirements, and special controls structure before filing — substantially reducing RTA risk.
De Novo is the FDA pathway for novel low-to-moderate risk devices that lack a valid predicate for 510(k) clearance but do not require full PMA. It is commonly used for AI/ML-based devices and other innovative device types where no cleared equivalent exists.
The De Novo applicant's device becomes the first classified device in a new product code — and the predicate every future competitor must reference in their 510(k) submissions. This first-mover advantage shapes competitive positioning for years after clearance.
Special controls are device-specific, testable requirements — performance standards, design characteristics, testing methods, and labeling specifications — that FDA determines are necessary for reasonable assurance of safety and effectiveness. They are the regulatory heart of every De Novo application.
Get Started
Many novel devices that went through expensive, failed 510(k) attempts were De Novo candidates from the start. Let's assess your device's regulatory profile before you commit to a pathway.